Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $13.48 Analyst target: $31.50 Upside: 133.68%
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, is focused on developing candidates for protease products in the fields of hemostasis and complement regulation. The company is headquartered in South San Francisco, California.
See the full interactive analysis & chart →Informational only — not investment advice.